ABT Net income
Net income at Abbott Laboratories fell to $6.5B in fiscal 2025, from $13.4B in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 1800 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$6.5B
FY2024 $13.4B
HIGH$13.4B FY2024
LOW$5.7B FY2023
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $6.5B | $-6.9B |
| FY2024 | $13.4B | +$7.7B |
| FY2023 | $5.7B | $-1.2B |
| FY2022 | $6.9B | $-138M |
| FY2021 | $7.1B | — |
More SAME DATA, OTHER VIEWS
Net income across coverage → · ABT company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.